<?xml version="1.0" encoding="utf-8" ?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>ATOSSA GENETICS 2 RSS Feed | Nachrichten - www.finanzen.net</title><description>www.finanzen.net bietet Finanznachrichten zum weltweiten Börsengeschehen</description><category>Finanzen</category><link>https://www.finanzen.net</link><language>de-de</language><copyright>finanzen.net GmbH</copyright><lastBuildDate>Fri, 19 Jun 2026 17:50:50 +0200</lastBuildDate><atom:link href="https://www.finanzen.net/rss/atossa%5Fgenetics%5F2%2Drss%2Dfeed" rel="self" type="application/rss+xml"/><image><url>https://images.finanzen.net/images/finanzen_net_neu.gif</url><title>ATOSSA GENETICS 2 RSS Feed | Nachrichten - www.finanzen.net</title><link>https://www.finanzen.net</link></image><item><title>Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer</title><pubDate>Tue, 06 Jan 2026 14:15:00 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/atossa-therapeutics-receives-fda-study-may-proceed-letter-for-z-endoxifen-investigational-new-drug-application-for-metastatic-breast-cancer-15395280</link><description><![CDATA[<p><p xmlns="http://www.w3.org/1999/xhtml"><span class="legendSpanClass"><span class="xn-location">SEATTLE, <span class="legendSpanClass"><span class="xn-chron">Jan. 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/atossa-therapeutics-receives-fda-study-may-proceed-letter-for-z-endoxifen-investigational-new-drug-application-for-metastatic-breast-cancer-15395280</guid></item></channel></rss>
